KR20010040932A - 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신 - Google Patents

인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신 Download PDF

Info

Publication number: KR20010040932A
Authority: KR; South Korea
Prior art keywords: aloh; rsv; protein; interleukin; mice
Prior art date: 1998-02-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020007008845A

Other languages

English (en)

Korean (ko)

Inventor

핸콕제랄드이.

엘드릿지존에이치.

Original Assignee

윌리암 에이취 캘넌, 에곤 이 버그

아메리칸사이아나미드컴파니

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-12

Filing date

1999-02-10

Publication date

2001-05-15

1999-02-10 Application filed by 윌리암 에이취 캘넌, 에곤 이 버그, 아메리칸사이아나미드컴파니 filed Critical 윌리암 에이취 캘넌, 에곤 이 버그

2001-05-15 Publication of KR20010040932A publication Critical patent/KR20010040932A/ko

Status Withdrawn legal-status Critical Current

Links

108010065805 Interleukin-12 Proteins 0.000 title claims abstract description 237
102000013462 Interleukin-12 Human genes 0.000 title claims abstract description 237
229960005486 vaccine Drugs 0.000 title claims abstract description 84
108091007433 antigens Proteins 0.000 title claims abstract description 68
102000036639 antigens Human genes 0.000 title claims abstract description 68
239000000427 antigen Substances 0.000 title claims abstract description 67
229940117681 interleukin-12 Drugs 0.000 title claims description 234
230000003612 virological effect Effects 0.000 title claims description 3
230000000241 respiratory effect Effects 0.000 title claims 3
239000000203 mixture Substances 0.000 claims abstract description 43
230000028993 immune response Effects 0.000 claims abstract description 34
229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 24
239000011707 mineral Substances 0.000 claims abstract description 24
239000000725 suspension Substances 0.000 claims abstract description 24
241000725643 Respiratory syncytial virus Species 0.000 claims description 64
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 60
108091006027 G proteins Proteins 0.000 claims description 26
108091000058 GTP-Binding Proteins 0.000 claims description 26
102000030782 GTP binding Human genes 0.000 claims description 24
239000002671 adjuvant Substances 0.000 claims description 22
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 21
241000700605 Viruses Species 0.000 claims description 18
238000000034 method Methods 0.000 claims description 14
230000002163 immunogen Effects 0.000 claims description 13
229940037003 alum Drugs 0.000 claims description 10
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
108010053187 Diphtheria Toxin Proteins 0.000 claims description 4
102000016607 Diphtheria Toxin Human genes 0.000 claims description 4
108010055044 Tetanus Toxin Proteins 0.000 claims description 4
229940118376 tetanus toxin Drugs 0.000 claims description 4
108010081690 Pertussis Toxin Proteins 0.000 claims 3
239000007900 aqueous suspension Substances 0.000 claims 3
229940040731 human interleukin-12 Drugs 0.000 claims 3
230000001681 protective effect Effects 0.000 abstract description 19
241000699670 Mus sp. Species 0.000 description 114
210000002966 serum Anatomy 0.000 description 57
238000002255 vaccination Methods 0.000 description 55
210000004027 cell Anatomy 0.000 description 40
230000003472 neutralizing effect Effects 0.000 description 39
230000000694 effects Effects 0.000 description 38
108090000623 proteins and genes Proteins 0.000 description 35
102000004169 proteins and genes Human genes 0.000 description 34
108010002616 Interleukin-5 Proteins 0.000 description 29
102000000743 Interleukin-5 Human genes 0.000 description 29
229940100602 interleukin-5 Drugs 0.000 description 29
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 25
230000000295 complement effect Effects 0.000 description 23
210000004072 lung Anatomy 0.000 description 21
230000028996 humoral immune response Effects 0.000 description 20
208000015181 infectious disease Diseases 0.000 description 20
210000002443 helper t lymphocyte Anatomy 0.000 description 19
210000003979 eosinophil Anatomy 0.000 description 18
230000003053 immunization Effects 0.000 description 17
238000002649 immunization Methods 0.000 description 17
230000021633 leukocyte mediated immunity Effects 0.000 description 16
108010074328 Interferon-gamma Proteins 0.000 description 15
230000001419 dependent effect Effects 0.000 description 15
230000009885 systemic effect Effects 0.000 description 15
238000002965 ELISA Methods 0.000 description 14
238000007918 intramuscular administration Methods 0.000 description 14
102100037850 Interferon gamma Human genes 0.000 description 13
230000006698 induction Effects 0.000 description 13
239000012530 fluid Substances 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
230000009467 reduction Effects 0.000 description 12
230000028709 inflammatory response Effects 0.000 description 10
230000002195 synergetic effect Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
230000036039 immunity Effects 0.000 description 8
238000006386 neutralization reaction Methods 0.000 description 8
230000002458 infectious effect Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
238000013461 design Methods 0.000 description 6
230000004927 fusion Effects 0.000 description 6
238000005342 ion exchange Methods 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
210000004988 splenocyte Anatomy 0.000 description 6
239000013592 cell lysate Substances 0.000 description 5
230000001461 cytolytic effect Effects 0.000 description 5
244000052769 pathogen Species 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
230000037361 pathway Effects 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
201000009732 pulmonary eosinophilia Diseases 0.000 description 5
210000000689 upper leg Anatomy 0.000 description 5
230000024932 T cell mediated immunity Effects 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
-1 ethanol polyols Chemical class 0.000 description 4
210000002865 immune cell Anatomy 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
206010014950 Eosinophilia Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241001529936 Murinae Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000003607 modifier Substances 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
231100000699 Bacterial toxin Toxicity 0.000 description 2
206010057248 Cell death Diseases 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
241000712003 Human respirovirus 3 Species 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
239000000688 bacterial toxin Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102000003812 Interleukin-15 Human genes 0.000 description 1
108090000172 Interleukin-15 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229940124679 RSV vaccine Drugs 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003141 anti-fusion Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
108700003601 dimethylglycine Proteins 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
230000022023 interleukin-5 production Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000051 modifying effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
231100001083 no cytotoxicity Toxicity 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000012128 staining reagent Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
229940124856 vaccine component Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

KR1020007008845A 1998-02-12 1999-02-10 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신 Withdrawn KR20010040932A (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7445098P	1998-02-12	1998-02-12
US60/074,450		1998-02-12
PCT/US1999/002848 WO1999040937A2 (fr)	1998-02-12	1999-02-10	Vaccins renfermant l'interleukine-12 et antigenes du virus respiratoire syncytial

Publications (1)

Publication Number	Publication Date
KR20010040932A true KR20010040932A (ko)	2001-05-15

Family

ID=22119624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020007008845A Withdrawn KR20010040932A (ko)	1998-02-12	1999-02-10	인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신

Country Status (9)

Country	Link
EP (1)	EP1053016A2 (fr)
JP (1)	JP2002502883A (fr)
KR (1)	KR20010040932A (fr)
CN (1)	CN1295480A (fr)
AU (1)	AU2596699A (fr)
BR (1)	BR9907885A (fr)
CA (1)	CA2320042A1 (fr)
IL (1)	IL137810A0 (fr)
WO (1)	WO1999040937A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ515322A (en)	1999-05-13	2004-03-26	Wyeth Corp	Adjuvant combination formulations
AU2001270031B2 (en) *	2000-06-22	2005-11-03	Wyeth Holdings Corporation	QS-21 and IL-12 as an adjuvant combination
US20030129161A1 (en) *	2001-09-17	2003-07-10	Hsien-Jue Chu	Interleukin-12 as a veterinary vaccine adjuvant
CN108300705B (zh) *	2017-01-12	2021-10-22	厦门大学	稳定呼吸道合胞病毒融合蛋白的方法
CN110684747B (zh)	2018-07-06	2024-05-24	厦门大学	灭活及保存呼吸道合胞病毒的方法
CN118141910B (zh) *	2024-04-03	2025-10-28	河北医科大学	甲基转移酶抑制剂作为呼吸道合胞病毒疫苗及过敏疫苗佐剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571515A (en) *	1994-04-18	1996-11-05	The Wistar Institute Of Anatomy & Biology	Compositions and methods for use of IL-12 as an adjuvant
DK0784486T3 (da) *	1994-10-05	2006-08-14	Univ Vanderbilt	Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
GB9422990D0 (en) *	1994-11-15	1995-01-04	Cortecs Ltd	Immunogenic compositions

1999
- 1999-02-10 EP EP99905925A patent/EP1053016A2/fr not_active Withdrawn
- 1999-02-10 CN CN99804658A patent/CN1295480A/zh active Pending
- 1999-02-10 KR KR1020007008845A patent/KR20010040932A/ko not_active Withdrawn
- 1999-02-10 JP JP2000531188A patent/JP2002502883A/ja active Pending
- 1999-02-10 IL IL13781099A patent/IL137810A0/xx unknown
- 1999-02-10 WO PCT/US1999/002848 patent/WO1999040937A2/fr not_active Ceased
- 1999-02-10 CA CA002320042A patent/CA2320042A1/fr not_active Abandoned
- 1999-02-10 BR BR9907885-6A patent/BR9907885A/pt not_active Application Discontinuation
- 1999-02-10 AU AU25966/99A patent/AU2596699A/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1295480A (zh)	2001-05-16
WO1999040937A2 (fr)	1999-08-19
WO1999040937A3 (fr)	1999-10-28
BR9907885A (pt)	2000-11-14
AU2596699A (en)	1999-08-30
JP2002502883A (ja)	2002-01-29
IL137810A0 (en)	2001-10-31
EP1053016A2 (fr)	2000-11-22
CA2320042A1 (fr)	1999-08-19

Legal Events

Date	Code	Title	Description
2000-08-11	PA0105	International application	Patent event date: 20000811 Patent event code: PA01051R01D Comment text: International Patent Application
2001-05-15	PG1501	Laying open of application
2004-02-11	PC1203	Withdrawal of no request for examination
2004-02-11	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid

Publication	Publication Date	Title
AU648509B2 (en)	1994-04-28	Stable vaccine compositions containing interleukins
CN1292706A (zh)	2001-04-25	用白细胞介素－12配制的肺炎球菌和脑膜炎球菌疫苗
EP0482068A1 (fr)	1992-04-29	Cytokine et supports d'hormone pour vaccins conjugues
CA2409406C (fr)	2010-09-14	Qs-21 et il-12 utilises comme combinaison d'adjuvants
KR100622716B1 (ko)	2006-09-13	인터루킨-12 및 허피스 심플렉스 바이러스 항원을포함하는 백신
AU2001270031A1 (en)	2002-03-21	QS-21 and IL-12 as an adjuvant combination
CA2215968A1 (fr)	1996-10-03	Methode d'amelioration de la reponse d'anticorps a des antigenes specifiques avec l'interleukine-10
AU758111B2 (en)	2003-03-13	Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
EP1178825B1 (fr)	2011-07-13	Preparations de combinaisons d'adjuvants
KR20010040932A (ko)	2001-05-15	인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신
EP0913157B1 (fr)	2004-04-28	Vaccin composite contenant un antigene, un anticorps et un adn recombinant et son procede de preparation
KR20070048140A (ko)	2007-05-08	온코세르카 볼불러스의 천연 생성물의 항원보강성 및 면역강화 특성
KR100863368B1 (ko)	2008-10-13	조합 보조 제제
MXPA00007881A (en)	2002-03-26	Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
MXPA00007878A (fr)	2002-03-26